nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.06.2012 | Neuro-Oncology (LE Abrey, Section Editor)

Chemotherapy-Related Cognitive Dysfunction

verfasst von: Jeffrey S. Wefel, Sanne B. Schagen

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Many cancer patients develop treatment-related cognitive dysfunction that affects their quality of life and can result in diminished functional independence. There is an emerging body of transdisciplinary research demonstrating that chemotherapeutic agents can produce neurobiological changes within the brain, which are associated with a constellation of cognitive changes that can result in decreased quality of life and functional independence. The increased incidence of cancer, coupled with longer survival times, has resulted in larger numbers of cancer survivors who are struggling with this neurotoxicity. This review summarizes the neuropsychological findings in patients with breast and brain cancer who receive systemic chemotherapy as well as the recent animal and imaging research elucidating the mechanisms by which these therapies impact brain structure, function, and consequent behavior.

Perry A, Schmidt RE. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathologica. 2006;111:197–212.PubMedCrossRef

Videnovic A, Semenow I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology. 2005;65:1792–4.PubMedCrossRef

• Dietrich J, Monje M, Wefel J, et al. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist. 2008;13:1285–95. This review summarizes the clinical spectrum of chemotherapy- and radiation therapy–associated neurotoxicity with special emphasis on cognitive dysfunction.PubMedCrossRef

Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer. 2004;90:1691–6.PubMed

Shah RR. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Expert Opinion Drug Safety. 2005;4:103–28.CrossRef

Sul JK, DeAngelis LM. Neurologic complications of cancer chemotherapy. Sem Oncol. 2006;33:324–32.CrossRef

Sheline GE. Radiation therapy of brain tumors. Cancer. 1977;39:873–81.PubMedCrossRef

Jansen C, Miakowski C, Dodd M, et al. Potential mechanisms for chemotherapy-induced impairments in cognitive function. Oncol Nursing Forum. 2005;32:1151–63.CrossRef

Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245:695–708.PubMedCrossRef

10.

Delattre JY, Posner JB. Neurological complications of chemotherapy and radiation therapy. In: Aminoff MJ, editor. Neurology and general medicine. Secondth ed. New York: Churchill Livingstone; 1995. p. 421–45.

11.

Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology. 1995;4:61–6.CrossRef

12.

van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Canc Inst. 1998;90(3):210–8.CrossRef

13.

Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50.PubMedCrossRef

14.

Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):2695–701.PubMed

15.

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, et al. Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.PubMedCrossRef

16.

Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13(9):1387–97.PubMedCrossRef

17.

Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21(22):4175–83.PubMedCrossRef

18.

Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955–69.PubMedCrossRef

19.

Wefel JS, Lenzi R, Theriault R, et al. Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004;101(3):466–75.PubMedCrossRef

20.

Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9.PubMedCrossRef

21.

Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14(1):70–8.PubMedCrossRef

22.

Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104(11):2499–507.PubMedCrossRef

23.

Mar Fan HG, Houede-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol. 2005;23(31):8025–32.CrossRef

24.

Shilling V, Jenkins V, Morris R. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast. 2005;14(2):142–50.PubMedCrossRef

25.

Yoshikawa E, Matsuoka Y, Inagaki M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Canc Res Treat. 2005;92(1):81–4.CrossRef

26.

Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15(5):422–30.PubMedCrossRef

27.

Hurria A, Rosen C, Hudis C, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54(6):925–31.PubMedCrossRef

28.

Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109(1):146–56.PubMedCrossRef

29.

Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34.PubMedCrossRef

30.

Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Canc Inst. 2006;98(23):1742–5.CrossRef

31.

Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006;17(3):415–23.PubMedCrossRef

32.

Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Canc Res Treat. 2008;110(1):143–52.CrossRef

33.

Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–13.PubMedCrossRef

34.

• Abraham J, Haut MW, Moran MT, et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer. 2008;8(1):88–91. This article is among the first to describe chemotherapy-associated changes in cerebral white matter related to cognitive deficits experienced by breast cancer patients.PubMedCrossRef

35.

Minisini AM, De Faccio S, Ermacora P, et al. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol. 2008;67(1):71–9. Epub 2008 Apr 3.PubMedCrossRef

36.

Jansen CE, Dodd MJ, Miaskowski CA, et al. A longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology. 2008;17(12):1189–95.PubMedCrossRef

37.

Stewart A, Collins B, Mackenzie J, et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology. 2008;17(2):122–30.PubMedCrossRef

38.

Kreukels BP, van Dam FS, Ridderinkhof KR, et al. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer. 2008;8(1):80–7.PubMedCrossRef

39.

Weis J, Poppelreuter M, et al. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psycho-Oncology. 2009;18(7):775–82.PubMedCrossRef

40.

Collins B, Mackenzie J, Stewart A, et al. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology. 2009;18(2):134–43.PubMedCrossRef

41.

Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 2009;48(1):76–85.PubMedCrossRef

42.

Jim HS, Donovan KA, Small BJ, et al. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115(8):1776–83.PubMedCrossRef

43.

Kesler SR, Bennett FC, Mahaffey ML, et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res. 2009;15(21):6665–73.PubMedCrossRef

44.

Mehlsen M, Pedersen AD, Jensen AB, et al. No indications of cognitive side effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology. 2009;18(3):248–57.PubMedCrossRef

45.

Ouimet LA, Stewart A, Collins B, et al. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol. 2009;31(1):73–89.PubMedCrossRef

46.

Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Canc Res Treat. 2009;116(1):113–23.CrossRef

47.

• Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27(4):415–34. This manuscript provides important insights into the functional impact of chemotherapy-related cognitive dysfunction.PubMedCrossRef

48.

Vearncombe KJ, Rolfe M, Wright M, et al. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15(6):951–62.PubMedCrossRef

49.

Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–40.PubMedCrossRef

50.

Cimprich B, Reuter-Lorenz P, Nelson J, et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol. 2010;32(3):324–31. Epub 2009 Jul 29.PubMedCrossRef

51.

de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206–19.PubMedCrossRef

52.

Debess J, Riis JO, Engebjerg MC, et al. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Canc Res Treat. 2010;121(1):91–100.CrossRef

53.

Jansen CE, Cooper BA, Dodd MJ, et al. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2011;19(10):1647–56.CrossRef

54.

Kvale EA, Clay OJ, Ross-Meadows LA, et al. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care. 2010;19(1):110–7.CrossRef

55.

Reid-Arndt SA, Hsieh C, Perry MC. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psycho-Oncology. 2010;19(5):535–44.PubMedCrossRef

56.

Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Canc Res Treat. 2010;123(1):25–34.CrossRef

57.

• Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56. This prospective study shows that standard-dose chemotherapy is associated with decline in cognitive functioning during and shortly after chemotherapy, and indicates the occurrence of new delayed cognitive decline in a considerable proportion of patients.PubMedCrossRef

58.

Yamada TH, Denburg NL, Beglinger LJ, et al. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22(1):48–54.PubMedCrossRef

59.

Kesler SR, Kent JS, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.PubMedCrossRef

60.

• Deprez S, Amant F, Yigit R, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp. 2011;32(3):480–93. This study demonstrates that DTI provides white matter integrity parameters that are sensitive to investigate neural changes related to cognitive problems in cancer patients following chemotherapy.PubMedCrossRef

61.

Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care 2011, doi: 10.1111/j.1365-2354.2011.01320.x. [Epub ahead of print]

62.

Koppelmans V, Breteler MMB, Boogerd W, et al. Neuropsychological performance in breast cancer survivors more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology 2012; in press

63.

Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201.PubMedCrossRef

64.

Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294–300. Epub 2010 Feb 8.PubMedCrossRef

65.

Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 2011;13:353–61.PubMedCrossRef

66.

Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13:660–8.PubMedCrossRef

67.

Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the CNS. Int J Radiat Oncol Biol Phys. 2011;79:1487–95.PubMedCrossRef

68.

Wefel JS, Armstrong TS, Wang M et al. Clinical utility of neurocognitive function as a prognostic factor for survival and measure of differential between-arm treatment effects on RTOG 0525. Presented at the 2011 Society for Neuro-Oncology Meeting in Collaboration with the AANS/CNS Section on Tumors. Orange County, CA; November 17-20, 2011.

69.

Hilverda K, Bosma I, Heimans JJ, et al. Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol. 2010;97:89–94.PubMedCrossRef

70.

Radiation Therapy Oncology Group: RTOG 9402 Finds Chromosomal Abnormality be a Strong Indicator for Determining Treatment and Outcome for Patients with Oligodendroglioma Brain Tumors. Available at http://www.rtog.org/News/tabid/72/articleType/ArticleView/articleId/31/RTOG-9402-Finds-Chromosomal-Abnormality-be-a-Strong-Indicator-for-Determining-Treatment-and-Outcome-for-Patients-with-Oligodendroglioma-Brain-Tumors.aspx. Accessed February 2012.

71.

Levin VA, Yung WKA, Bruner J, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of analplastic gliomas. Int J Radiat Oncol Biol Phys. 2002;53:58–66.PubMedCrossRef

72.

Groves MD, Maor MH, Meyers C, et al. A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1999;45:127–35.PubMedCrossRef

73.

Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007;18:1145–51.PubMedCrossRef

74.

Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91:315–21.PubMedCrossRef

75.

Brown MS, Simon JH, Stemmer SM, et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR Am J Neuroradiol. 1995;16(10):2013–20.PubMed

76.

Choi SM, Lee SH, Yang YS, et al. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16(3):328–34.PubMed

77.

Ferguson RJ, McDonald BC, Saykin AJ, et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866–70.PubMedCrossRef

78.

de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 2011;In Press.

79.

Koppelmans V, de Ruiter MB, van der Lijn F et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2011, Epub Dec 29.

80.

Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. AJNR Am J Neuroradiol. 1998;19(2):217–21.PubMed

81.

• McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819–28. This study is the first study showing evidence of longitudinal changes in cognitive functioning and cerebral white matter integrity after chemotherapy as well as an association between both.PubMedCrossRef

82.

Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.PubMedCrossRef

83.

Scherling C, Collins B, Mackenzie J, et al. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci 2011,5:122 Epub Nov 1.

84.

•• Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev. 2011;35:729–41. This manuscript comprehensively reviews the recent animal literature regarding the effects of different classes of cytotoxic agents on behavior and neurobiology.PubMedCrossRef

85.

Monje M, Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behavioral Brain Research. 2011;227:376–9.CrossRef

86.

Gong X, Schwartz PH, Linskey ME, et al. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology. 2011;76:1126–34.PubMedCrossRef

87.

• Konat GW, Kraszpulski M, James I, et al. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008;23:325–33. This study shows that N-acetyl cysteine ameliorated cognitive impairment due to cyclophosphamide and doxorubicin co-treatment, suggesting that oxidative stress may in part cause cognitive impairment associated with chemotherapy.PubMedCrossRef

88.

Lyons L, Elbeltagy M, Bennett G, et al. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS ONE 2012, Epub January 2012.

89.

Vijayanathan V, Gulinello M, Ali N, et al. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behavioral Brain Research. 2011;225:491–7.CrossRef

90.

Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment and Trojan horses. Clin Cancer Res. 2007;13:1663–74.PubMedCrossRef

91.

Lockman PR, Mittapali RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–78.PubMedCrossRef

92.

• Wefel JS, Vardy J, Ahles T, et al. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12:703–8. This manuscript describes methodological challenges in this literature and recommends study designs, cognitive tests, and analytical methods to help harmonize clinical research in this area.PubMedCrossRef

93.

van den Bent M, Wefel J, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.PubMedCrossRef

Titel: Chemotherapy-Related Cognitive Dysfunction
verfasst von: Jeffrey S. Wefel
Sanne B. Schagen
Publikationsdatum: 01.06.2012
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 3/2012
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-012-0264-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma

Recent Advances in the Genetics of Cerebellar Ataxias

Schizophrenia Genetics: Putting All the Pieces Together

Radiation Necrosis: Relevance with Respect to Treatment of Primary and Secondary Brain Tumors

What We Know about the Generation of Nystagmus and Other Ocular Oscillations: Are We Closer to Identifying Therapeutic Targets?

Molecular Therapies for Tuberous Sclerosis and Neurofibromatosis